EXEL logo

EXELExelixis Inc

$53.00
$0.37
(0.69%)
Today
Closed $53.13
$0.13
(0.24%)
After Hours
Updated: 07:35 PM EDT
EarningsAug 4
Mkt Cap$13.35B
Vol1.58M
News
all
press releases
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
More News
News Placeholder
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
News Placeholder
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
News Placeholder
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
News Placeholder
Exelixis, Inc. (EXEL): Renaissance Technologies Likes This Stock
Exelixis, Inc. (EXEL): Renaissance Technologies Likes This Stock...
Yahoo! Finance: News
News Placeholder
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced...
Business Wire
News Placeholder
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies Global Healthcare Conference: Exelixis is scheduled to present at 11:05 a.m. ET / 8:05 a.m. PT on Wednesday, June 3 in New York...
Business Wire
News Placeholder
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX (cabozantinib), and its investigational oral kinase inhibitor, zanzalintinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 29 June 2 in Chicago. The...
Business Wire
News Placeholder
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
Zacks
<
1
2
...
>

Advertisement|Remove ads.